Review
Molecular targeted therapies for breast cancer treatment
-
* Corresponding author: Burkhard Brandt bu.brandt@uke.de
1 Department of Obstetrics and Gynecology, Breast Centre Klinikum Lüdenscheid, Academic Teaching Hospital of the University Bonn, Luedenscheid, Paulmannshoeher Str. 14 – 58515 Luedenscheid Germany
2 European Laboratory Association, Ibbenbueren, Roggenkampstr. 12 49477 Ibbenbueren Germany
3 Department of Experimental Surgery and Molecular Oncology, Faculty Mannheim, University Heidelberg, Molecular of Solid Tumors, German Cancer Research Center (DKFZ), Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim Germany
4 Institute for Tumor Biology, University Medical Center Hamburg-Eppendorf, Campus Forschung N 27 Martinistraße 52, 20246 Hamburg, Germany
Breast Cancer Research 2008, 10:211 doi:10.1186/bcr2112
Published: 24 July 2008Abstract
Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.